• PCN54 INCREASING EXPENDITURES FOR ONCOLOGY MEDICATIONS- CZECH REPUBLIC LONG-TERM DATA

    Nov 1, 2007, 00:00

  • PCN34 COST MINIMIZATION ANALYSIS OF INTRA-VENOUS BIPHOSPHONATES THERAPIES AVAILABLE IN BRAZIL FOR THE PROPHYLAXIS OF SKELETAL EVENTS (SE) IN BREAST CANCER PATIENTS WITH BONE METASTASIS

    Nov 1, 2007, 00:00

  • PUK17 ENDOSCOPIO INJECTION VERSUS ANTIBIOTIC PROPHYLAXIS IN THE REDUCTION OF URINARYTRACT INFECTIONS IN PATIENTS WITH VESICOURETERAL REFLUX

    Nov 1, 2007, 00:00

  • PND5 USE OF HEALTH CARE RESOURCES AND CORRESPONDING COSTS IN NEUROLOGICAL DISORDERS IN THE PRIMARY CARE SETTING

    Nov 1, 2007, 00:00

  • PCN74 PSYCHOSOCIAL CONSEQUENCES OF ABNORMAL AND FALSE-POSITIVE RESULTS IN LUNG CANCER SCREENING- ADAPTATION OF A QUESTIONNAIRE

    Nov 1, 2007, 00:00

  • PCN55 THE IMPACT OF 21-GENE RT-PCRASSAY ON REAL LIFE TREATMENT DECISIONS IN N−, ER+ EARLY-STAGE BREAST CANCER PATIENTS- IT'S IMPLICATION FOR BUDGET IMPACT ANALYSIS

    Nov 1, 2007, 00:00

  • PSM3 AN EVALUATION OF THE COST-EFFECTIVENESS OF AN EXTENDED COURSE OF VARENICLINE IN PREVENTING SMOKERS WHO HAVE QUIT FROM RELAPSING

    Nov 1, 2007, 00:00

  • PMH43 POTENTIAL DRUG-DRUG INTERACTIONS WITH RISPERIDONE AND THE RISK OF DISCONTINUATION- A RETROSPECTIVE ANALYSIS OF PATIENTS IN QUEBEC, CANADA

    Nov 1, 2007, 00:00

  • PND22 MILD TO MODERATE ALZHEIMER'S DISEASE ASSOCIATED WITH SIGNIFICANT TIME BURDEN TO CAREGIVERS

    Nov 1, 2007, 00:00

  • PSM4 HEALTH ECONOMIC MODEL OF SMOKING CESSATION TREATMENT WITH VARENICLINE IN GERMANY

    Nov 1, 2007, 00:00

  • PDB21 COST-EFFECTIVENESS OF STRICT “GET TO GOAL” TREATMENT DIRECTIVES IN THE TREATMENT OFYOUNGER PATIENTS WITH NEWLY DIAGNOSEDTYPE 2 DIABETES MELLITUS (T2DM)

    Nov 1, 2007, 00:00

  • EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

    Nov 1, 2007, 00:00

  • PEY8 A EUROPEAN SURVEY OF PATIENT SATISFACTION WITH SPECTACLES AND THE ASSOCIATED COSTS IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2007, 00:00

  • DB2 COMPARING BRITISH AND GERMAN DIABETES GUIDANCE WITH RESPECT TO LONGTERM OUTCOMES AND ASSOCIATED COSTS- RESULTS FROMTHE EAGLE DIABETES SIMULATION MODEL

    Nov 1, 2007, 00:00

  • PND23 A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS TREATED WITH GLATIRAMER ACETATE INJECTION OR HIGH-DOSE INTERFERON BETA-IA

    Nov 1, 2007, 00:00

  • Patient-Reported Outcomes to Support Medical Product Labeling Claims- FDA Perspective

    Nov 1, 2007, 00:00

  • PGI24 SPANISH CULTURAL ADAPTATION AND VALIDATION OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ)

    Nov 1, 2007, 00:00

  • PMH14 REMISSION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)- 12 MONTH INTERIM RESULTS FROM E-STAR PROJECT IN CZECH REPUBLIC AND SLOVAKIA

    Nov 1, 2007, 00:00

  • PMC1 COMPARISON OF EMR DATA TO US NATIONAL DATA

    Nov 1, 2007, 00:00

  • PCN73 LINGUISTIC VALIDATION OF THE HOT FLASH DIARY FOR PROSTATE CANCER PATIENTS IN EIGHT LANGUAGES FOR NINE COUNTRIES

    Nov 1, 2007, 00:00

  • PHP23 RELATIONSHIP BETWEEN RISKS FOR LIFESTYLE-RELATED DISEASES AND MEDICAL EXPENSES AFTER 10 YEARS OF METABOLIC SYNDROME

    Nov 1, 2007, 00:00

  • PND41 EFFECTIVENESS OF PRAMIPEXOLE IN THE TREATMENT OF RLS AND THE EFFECT ON WORK PRODUCTIVITY- A 12-WEEKS NON-INTERVENTIONAL TRIAL IN PATIENTS WITH PRIMARY RESTLESS LEGS SYNDROM (RLS)

    Nov 1, 2007, 00:00

  • PDB5 GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS

    Nov 1, 2007, 00:00

  • PAA8 COST OF REFRACTORY SEVERE PERSISTENT ASTHMA IN CZECH REPUBLIC—COST OF ILLNESS STUDY

    Nov 1, 2007, 00:00

  • PDB37 MEALTIME INSULIN ASPART REDUCES THE LONG-TERM COST OF COMPLICATIONS COMPARED TO HUMAN INSULIN AS PART OF BASAL-BOLUS THERAPY IN POLISH TYPE 2 DIABETES PATIENTS

    Nov 1, 2007, 00:00

  • PDB40 SIMULATION OF LONG-TERM COSTS OF COMPLICATIONS IN TYPE II DIABETES IN THE UNITED STATES

    Nov 1, 2007, 00:00

  • PCV36 COST-EFFECTIVENESS OF THE MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLAEMIA WITH A PREVENTIVE TREATMENT ATORVASTATIN-BASED

    Nov 1, 2007, 00:00

  • PCN46 A COST UTILITY ANALYSIS OF MAINTENANCE RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR NON HODGKINS LYMPHOMA (NHL) IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCN60 IMPLEMENTATION AND EVALUATION OF CLINICAL PATHWAYS IN AN ONCOLOGY ELECTRONIC MEDICAL RECORD

    Nov 1, 2007, 00:00

  • PMC3 FORMAL OBJECTIVE BAYESIAN METHODS IN COST-EFFECTIVENESS STUDIES

    Nov 1, 2007, 00:00

  • PMC28 EVALUATING THE EFFECTIVENESS OF SEARCH STRATEGIES FOR SYSTEMATIC REVIEWS

    Nov 1, 2007, 00:00

  • ND3 MODELING TREATING MULTIPLE SCLEROSISWITH DISEASE MODIFYING DRUGS USING DISCRETE EVENT SIMULATION

    Nov 1, 2007, 00:00

  • PMC29 ESTIMATING THE BUDGET IMPACT OF NEWTECHNOLOGIES ADDED TO THE NATIONAL LIST OF HEALTH BENEFITS IN ISRAEL- STAKEHOLDERS' INCENTIVES FOR ADOPTING A RISK-SHARING MECHANISM

    Nov 1, 2007, 00:00

  • PDB3 COMPARING EFFICIENCY OF INSULIN GLARGINE VS. NPH INSULIN IN PATIENTS WITHTYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • CN2 DEVELOPMENT ANDVALIDATION OF OPTIMALLYWEIGHTED MEASURES OF GLOBAL HEALTH-RELATED QUALITY OF LIFE (QOL) AND UTILITY BASED ON A CANCER-SPECIFIC QOL INSTRUMENT

    Nov 1, 2007, 00:00

  • PIN40 AN AUDIT OF HLA-B570I SCREENING METHODS AND COSTS IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PMC16 SF-6D REFERENCE VALUES FOR SPANISH GENERAL POPULATION

    Nov 1, 2007, 00:00

  • PDB65 THE PROSIT DISEASE MODELLING COMMUNITY—OPEN SOURCE DEVELOPMENT OF DECISION ANALYTIC DISEASE MODELS FOR TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PCV38 COST-EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION- A COMPARATIVE ANALYSIS USING CLINICAL TRIAL AND OBSERVATIONAL DATA

    Nov 1, 2007, 00:00

  • PIN43 ADAPTATION OF A HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER IN A WELL FUNCTIONING POPULATION-BASED SCREENING SYSTEM—A MODEL CALIBRATION TO FINLAND

    Nov 1, 2007, 00:00

  • PDB20 COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN AN ITALIAN SETTING. A META-ANALYSIS

    Nov 1, 2007, 00:00

  • PCV33 RESOURCE USE AND TREATMENT COSTS FORACUTE DECOMPENSATED HEART FAILURE- ECONOMIC ANALYSIS OF THE SURVIVE TRIAL

    Nov 1, 2007, 00:00

  • POS13 IMPACT OF THE ALLOWABLE GAP ON PERSISTENCE IN THE BISPHOSPHONATE MARKET

    Nov 1, 2007, 00:00

  • PDB45 THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND DIABETES-RELATED COSTS- EVIDENCE FROM A CLAIMS DATABASE

    Nov 1, 2007, 00:00

  • PDB9 INDIRECT COMPARISON OF ONCE DAILY INSULIN DETEMIR AND GLARGINE IN REDUCING WEIGHT GAIN AND ACHIEVING GLYCEMIC CONTROL, WHEN ADMINISTERED IN ADDITION TO CONVENTIONAL ORAL ANTIDIABETIC THERAPY IN THE TREATMENT OFTYPE 2 DIABETES PATIENTS; ...

    Nov 1, 2007, 00:00

  • PAR25 ASSOCIATION OF PERSISTENCE WITH ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPY AND HEALTH CARE COSTS IN PATIENTS WITH PSORIATIC ARTHRITIS

    Nov 1, 2007, 00:00

  • PSK11 EVALUATION OF THE ASSOCIATION BETWEEN EQ5D UTILITY AND DERMATOLOGY LIFE QUALITY INDEX (DLQI) SCORE IN PATIENTS WITH PSORIASIS

    Nov 1, 2007, 00:00

  • PAR15 IMPACT OF CO-MORBIDITY BURDEN ON REALWORLD HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTS INITIATING ANTI-TUMOR NECROSIS FACTOR THERAPY

    Nov 1, 2007, 00:00

  • PHP29 THE RELATIONSHIP BETWEEN PHYSICIAN EMPATHY AND SATISFACTION WITH PRIMARY CARE PHYSICIANS- FINDINGS FROM AN INTERNET BASED SURVEY

    Nov 1, 2007, 00:00

  • PUK23 ILLNESS REPRESENTATIONS IN RENAL TRANSPLANT RECIPIENTS

    Nov 1, 2007, 00:00

  • PMH21 THE COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE IN SWEDEN

    Nov 1, 2007, 00:00

  • PPN2 A COST MINIMIZATION ANALYSIS OF IV BOLUS VERSUS IV INFUSION DICLOFENAC IN POST-OPERATIVE PAIN

    Nov 1, 2007, 00:00

  • PIN21 COST-EFFECTIVENESS OF INFLUENZA VACCINATION FOR HEALTHY ADULTS IN THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PSU2/ES4 THE RELATIVE COST-EFFECTIVENESS OF THE FENTANYL HCL PATIENT-ACTIVATED TRANSDERMAL SYSTEM (ITS) IN ACUTE POST-OPERATIVE PAIN MANAGEMENT (POPM) IN GREECE

    Nov 1, 2007, 00:00

  • PEY9 COST OF STANDARD CARE TREATMENT IN THE UNITED KINGDOM AMONG PATIENTS WITH PROGRESSION OF PRIMARY OPEN ANGLE GLAUCOMA

    Nov 1, 2007, 00:00

  • PMH15 PREVALENCE OF TREATMENT RESISTANT DEPRESSION IN USUAL CARE IN THE UNITED STATES

    Nov 1, 2007, 00:00

  • PMH54 PRELIMINARY VALIDATION OF THE ENGLISH VERSION OF THE SCHIZOPHRENIA QUALITY OF LIFE (S-QOL) SCALE

    Nov 1, 2007, 00:00

  • HP4 PROMOTING A DRUG'S HEALTH ECONOMIC ADVANTAGES IN MEDICAL JOURNAL ADVERTISING IN THE U.S.- A REVIEW OF 3,500 ADS FROM 1990–2006

    Nov 1, 2007, 00:00

  • PHM22 THE EMOTIONAL AND PHYSICAL BURDEN OF INJECTIONS ON PATIENTS UNDERGOING IVF

    Nov 1, 2007, 00:00

  • PIH14 DESCRIBING YOUR HEALTH TODAY- ANALYSIS OF OPEN ANSWERS IN THE VALIDATION PROCEDURE OF THE ITALIAN EQ-5D (CHILD)VERSION

    Nov 1, 2007, 00:00

  • PCN30 THE ECONOMIC BENEFITS OFTEGAFURWITH URACIL (UFTORAL) IN FIRST- LINE METASTATIC COLORECTAL CANCER

    Nov 1, 2007, 00:00

  • PSM2 A COST—EFFECTIVENESS ANALYSIS OF A COMMUNITY PHARMACIST BASED SMOKING CESSATION PROGRAM IN THAILAND

    Nov 1, 2007, 00:00

  • PCV85 DOES A SINGLE PILL COMBINING AMLODIPINE AND ATORVASTATIN OFFER GREATER LONG-TERM ADHERENCE BENEFIT OVER LOW-COST GENERIC 2-PILL CALCIUM CHANNEL BLOCKER/STATIN REGIMENS?

    Nov 1, 2007, 00:00

  • PMC19 USE OF THE RELIABLE CHANGE INDEX TO EVALUATE CLINICAL SIGNIFICANCE IN HEART TRANSPLANTS

    Nov 1, 2007, 00:00

  • PCN24 COST-EFFECTIVENESS ANALYSIS OF 5HT3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

    Nov 1, 2007, 00:00

  • PAA1 SUB-ACUTE LACK OF ASTHMA CONTROL AND SUBSEQUENT ACUTE ASTHMA EXACERBATIONS- EVIDENCE FROM MANAGED CARE DATA

    Nov 1, 2007, 00:00

  • PAA10 ADULT ASTHMA- A COHORT ANALYSIS OF USE AND COST OF HOSPITAL AND EMERGENCY DEPARTMENT CARE BY LOCATION OF RESIDENCE OVERTWELVE MONTHS

    Nov 1, 2007, 00:00

  • PRS16 DEVELOPMENT OF PREFERENCE-BASED EQ-5D UTILITY VALUES FORTHE ST GEORGE'S RESPIRATORY QUESTIONNAIRE-CHRONIC OBSTRUCTIVE PULMONARY DISEASE (SGRQ-COPD)

    Nov 1, 2007, 00:00

  • PMC25 USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH CARE CHARACTERISTICS

    Nov 1, 2007, 00:00

  • PHP32 OBTAINING VALUE FOR MONEY FROM PHARMACEUTICALS- REFERENCE PRICING OR HEALTH TECHNOLOGY ASSESSMENT?

    Nov 1, 2007, 00:00

  • PIH15 ADJUSTING FORTRIAL QUALITY IN A META-ANALYSIS

    Nov 1, 2007, 00:00

  • What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures?

    Nov 1, 2007, 00:00

  • PND39 PATIENT-REPORTED OUTCOME (PRO) LABELING CLAIMS IN PARKINSON'S DISEASE- OVERVIEW OF US AND EUROPEAN DRUG APPROVALS

    Nov 1, 2007, 00:00

  • PCV15 IMPACT OF CHANGES IN REIMBURSEMENT SYSTEM ON THE BUDGET FROM THE PAYER'S AND PATIENT'S PERSPECTIVE

    Nov 1, 2007, 00:00

  • PMH49 SF-36 AND EQ-5D QUALITY OF LIFE INSTRUMENTS IN MAJOR DEPRESSIVE DISORDER PATIENTS- COMPARISONS OF TWO DIFFERENT TREATMENT OPTIONS

    Nov 1, 2007, 00:00

  • PAA13 THE MONTREAL PROTOCOL- CONCERNS OVER THE FUTURE TREATMENT OF ASTHMA

    Nov 1, 2007, 00:00

  • PRS14 THE IMPACT OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION ON QUALITY OF LIFE OF ASTHMA AND COPD PATIENTS

    Nov 1, 2007, 00:00

  • EC4 COST-EFFECTIVENESS AND COST-UTILITY OF RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN FRENCH SETTING

    Nov 1, 2007, 00:00

  • PMH4 EFFICACY OF ANTIPSYCHOTICS IN NEGATIVE SYMPTOMS OF SCHIZOPHRENIAS META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

    Nov 1, 2007, 00:00

  • PND13 COST-EFFECTIVENESS ANALYSIS OF THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY

    Nov 1, 2007, 00:00

  • PMH48 IMPACT OF COMORBIDITY ON EQ-5D-A STUDY OF HEALTH-RELATED QUALITY OF LIFE IN DEPRESSION IN A GENERAL POPULATION SURVEY

    Nov 1, 2007, 00:00

  • PG11 DETERMINATION OF MINIMAL IMPORTANT DIFFERENCES (MIDS) AND INTERPRETATION OF SF-36 SCORES IN PATIENTS SUFFERING FROM MODERATE-TO-SEVERE CROHN'S DISEASE

    Nov 1, 2007, 00:00

  • PIH3 ENDOMETRIOSIS-COST ESTIMATES AND METHODOLOGICAL PERSPECTIVE

    Nov 1, 2007, 00:00

  • PAR8 LEFLUNOMID VERSUS CYCLOSPORIN IN METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS IN POLAND-A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2007, 00:00

  • PMC26 UTILITY INDEX CALCULATION- SIMULATION STUDY CONSIDERING THE HEALTH STATUS AFTER AN INTERVENTION

    Nov 1, 2007, 00:00

  • PHM11 COST UTILITY OF KNEE SURGERYWITH RECOMBINANT ACTIVATED FACTORVII (RFVIIA) IN HEMOPHILIA PATIENTS WITH INHIBITORS- AN EXPLORATORY MODEL

    Nov 1, 2007, 00:00

  • PCV31 LONG-TERM COST-EFFECTIVENESS OF RIMONABANT IN GERMANY

    Nov 1, 2007, 00:00

  • PG13 BUDGET IMPACT OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAMME WITH ROTATEQ® IN FRANCE

    Nov 1, 2007, 00:00

  • PIN16 COST-EFFECTIVENESS OF AUGMENTIN ES®VS AZITHROMYCIN FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND

    Nov 1, 2007, 00:00

  • PMC17 ACCOUNTING FOR INITIAL HEALTH STATUS IN MEASURING THE BENEFITS OF HEALTH CARE TECHNOLOGIES

    Nov 1, 2007, 00:00

  • PMH20 RESOURCE USE AND COSTS ASSOCIATED WITH CHANGES IN ANTIDEPRESSANT TREATMENT IN A MANAGED CARE POPULATION WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2007, 00:00

  • PAR26 THE UNINTENDED CONSEQUENCES OF WITHDRAWING DRUGS FROMTHE MARKET

    Nov 1, 2007, 00:00

  • Evaluating Health-Related Quality of Life in Cancer Clinical Trials- The National Cancer Institute of Canada Clinical Trials Group Experience

    Nov 1, 2007, 00:00

  • PRS12 MAPPING THE EQ-5D FROM THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN A CLINICAL TRIAL OF COPD TREATMENTS—RESULTS FROM THE OPTIMAL TRIAL

    Nov 1, 2007, 00:00

  • PND31 DEVELOPMENT OF THE ALZHEIMER'S DISEASE CAREGIVER PREFERENCE QUESTIONNAIRE

    Nov 1, 2007, 00:00

  • PMC21 INFLUENCE OF “SOCIAL” AND “SCHOOL” LIFE DIMENSIONS ON CHILDREN'S QUALITY OF LIFE ASSESSED WITH EQ-5D (CHILD)

    Nov 1, 2007, 00:00

  • PND10 COST EFFECTIVENESS ANALYSES OF RUFINAMIDEVS TOPIRAMATE AND LAMOTRIGINE AS ADJUNCTIVE THERAPIES IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME (LGS) IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PIN39 ECONOMIC EVALUATION OF A UNIVERSAL CHILDHOOD PNEUMOCOCCAL CONJUGATE VACCINATION STRATEGY IN IRELAND

    Nov 1, 2007, 00:00

  • PRS2 A COST-MINIMIZATION ANALYSIS COMPARING MOXIFLOXACIN VERSUS LEVOFLOXACIN AND CEFTRIAXONE FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA- RESULTS FROM THE MOTIVTRIAL

    Nov 1, 2007, 00:00

  • PCN75 WHAT CHOICES DO MEN FEEL THEY HAVE IN SELECTION OF PROSTATE CANCER TREATMENT?

    Nov 1, 2007, 00:00

  • PDB17 MEDICAL COSTS AMONG INDIVIDUALS WITH DIABETES, HYPERTENSION OR HYPERCHOLESTEROLEMIA

    Nov 1, 2007, 00:00

  • PIN47 DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF THE VACCINEES' PERCEPTION OF INJECTION (VAPI) QUESTIONNAIRE TO ASSESS SUBJECTS' ACCEPTANCE OF INFLUENZA VACCINATION

    Nov 1, 2007, 00:00

  • PAR4 ASSOCIATION BETWEEN SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) AND HEALTH CARE COSTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PMC6 THE OPERATIVE INTERVAL OF AN INCREMENTAL COST-EFFECTIVENESS RATIO-A NEW BENCHMARK FOR ASSESSING THE BOUNDARIES ON THE EFFICIENT FRONTIER CURVE

    Nov 1, 2007, 00:00

  • PCV52 ATTITUDES AND BELIEFS OF PHYSICIANS ABOUT HYPERCHOLESTEROLEMIA IN SPAIN-THE PRACTICE STUDY

    Nov 1, 2007, 00:00

  • PHP20 THE GENERIC COST-EFFECTIVENESS OF HEALTH CARE

    Nov 1, 2007, 00:00

  • PHP7 INTERNATIONAL COMPARISON OF GENERIC MEDICINE PRICES

    Nov 1, 2007, 00:00

  • PHM12 COST-EFFECTIVENESS OF DASATINIBVS IMATINIB 800 MG/ DAY IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN

    Nov 1, 2007, 00:00

  • PAA23 THE RELATIONSHIP BETWEEN QUALITY OF LIFE AND WILLINGNESS TO PAY IN PATIENTS WITH ASTHMA IN KOREA

    Nov 1, 2007, 00:00

  • PDB1 GLYCEMIC CONTROL GOAL ATTAINMENT AMONGTYPE 2 DIABETIC PATIENTSWHO INITIATED ORAL COMBINATION THERAPY IN HUNGARY

    Nov 1, 2007, 00:00

  • MD1 IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

    Nov 1, 2007, 00:00

  • PCV4 META-ANALYSIS OF THE EFFICACY OF TELMISARTAN ON BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION

    Nov 1, 2007, 00:00

  • PMH53 ADHERENCE AND SWITCHING WITH ANTIDEPRESSANTS

    Nov 1, 2007, 00:00

  • PCV27 ECONOMIC EVALUATION OF NEBIVOLOL COMPARED WITH PLACEBO IN ELDERLY PATIENTS WITH HEART FAILURE -A MODEL BASED ANALYSIS ALONGSIDE THE SENIORS TRIAL

    Nov 1, 2007, 00:00

  • PUK7 A COST-MINIMIZATION ANALYSIS OF OXYBUTYNIN (TRANSDERMAL DELIVERY SYSTEM) COMPARED TO TOLTERODINE (TABLETS) IN THE TREATMENT OF PATIENTS WITH URGE OR MIXED URINARY INCONTINENCE IN SWEDEN

    Nov 1, 2007, 00:00

  • ES6 COST COMPARISON BETWEEN HAEMODIALYSIS AND PERITONEAL DIALYSIS IN NORWAY FOR PATIENTSWHO CAN USE EITHER TREATMENT MODALITY

    Nov 1, 2007, 00:00

  • EC1 RESOURCE USE AND COST OF DIAGNOSTICWORKUP OF WOMEN WITH SUSPECTED BREAST CANCER

    Nov 1, 2007, 00:00

  • PCN65 RESULTS FROM MABEL- QUALITY OF LIFE OF PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC)

    Nov 1, 2007, 00:00

  • PCN47 COST-UTILITY ANALYSIS OF OXALIPLATIN IN THE ADJUVANT TREATMENT OF COLON CANCER IN HUNGARY

    Nov 1, 2007, 00:00

  • PIN33 THE COST OF ZOSTERAND POST-HERPETIC NEURALGIA TREATMENT IN FRANCE

    Nov 1, 2007, 00:00

  • PCV82 FACTORS INFLUENCING COMPLIANCE WITH COMBINATION ANTIHYPERTENSIVE PHARMACOTHERAPY IN A LARGE US DATABASE

    Nov 1, 2007, 00:00

  • PIN9 A COST-EFFECTIVENESS ANALYSIS OF A YEARLY FIBROSCAN® LIVER FIBROSIS ASSESSMENT COMPARED WITH A PERIODIC LIVER BIOPSY IN HEPATITIS C VIRUS (HCV) INFECTED INDIVIDUALS IN A FRENCH SETTING

    Nov 1, 2007, 00:00

  • PHM5 ADVATE IS COST-EFFECTIVE INVESTMENT IN HEMOPHILIA A TREATMENT WHEN PATHOGENS EMERGE—A SCENARIO-BASED ECONOMIC AND POSITIVE INVESTMENT INTERVAL (Pll) EVALUATION

    Nov 1, 2007, 00:00

  • PCV3 EFFECTIVENESS OF ROSUVASTATIN COMPARED TO OTHER STATINS FORTHE PREVENTION OF FATAL AND NON-FATAL CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE— AN EPIDEMIOLOGICAL STUDY

    Nov 1, 2007, 00:00

  • PIN36 COST-UTILITY OF PEGINTERFERON-ALFA-2A (40 KD) IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B WITH AND WITHOUT THE “E” ANTIGEN IN BRAZIL

    Nov 1, 2007, 00:00

  • POB2 REDUCING GLOBAL CARDIOMETABOLIC RISK IN OVERWEIGHT OR OBESE INDIVIDUALS WITH DYSLIPIDEMIA- PROJECTED BENEFITS OF RIMONABANT IN A REAL WORLD POPULATION

    Nov 1, 2007, 00:00

  • PCV42 ANTICOAGULATION CONTROL IN DIFFERENT SETTINGS OF CARE- PERCEPTION, DIRECT NON-HEALTH CARE COSTS AND PRODUCTIVITY LOSSES AMONGST PATIENTS WITH ATRIAL FIBRILLATION IN AN ITALIAN REGION

    Nov 1, 2007, 00:00

  • PAA22 STATE TRANSITION MODELS FOR ESTIMATING TRANSITION PROBABILITIES IN MARKOV MODELS

    Nov 1, 2007, 00:00

  • PUK9 HEALTH STATUS AND COSTS OF PATIENTS UNDERGOING HAEMODIALYSISTREATMENT IN HUNGARY

    Nov 1, 2007, 00:00

  • ED1 COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN A GERMAN SETTING. A MODELING EVALUATION BASED UPON RESULTS FROM A META-ANALYSIS

    Nov 1, 2007, 00:00

  • HP1 HEALTH SYSTEM CORRELATES OF RECEIPT OF RADIATION AFTER BREAST CONSERVING SURGERY IN LOW-INCOME MEDICAID-ENROLLEDWOMEN

    Nov 1, 2007, 00:00

  • PMC31 EVALUATION OF THE PERSPECTIVE AND TYPE OF STUDIES IN ANIMAL HEALTH ECONOMICS

    Nov 1, 2007, 00:00

  • POS5 LITERATURE REVIEW ON THE COSTS OF NON-COMPLIANCE IN OSTEOPOROSIS

    Nov 1, 2007, 00:00

  • PDB46 COST-UTILITY OF INSULIN DETEMIR VERSUS NPH FOR TYPE I DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A FRENCH SETTING, A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OF THREE CLINICAL TRIALS

    Nov 1, 2007, 00:00

  • PAR27 WITHDRAWAL OF ROFECOXIB FROMTHE MARKET; THERAPEUTIC AND ECONOMIC IMPLICATION FOR THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PGI23 USING DISCRETE CHOICE EXPERIMENTS (DCE)TO MEASURE PREFERENCES FOR TREATMENT OPTIONS- AN APPLICATION TO GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

    Nov 1, 2007, 00:00

  • PMH30 DIRECT COSTS ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE

    Nov 1, 2007, 00:00

  • PDB73 PSYCHOMETRIC EVALUATION OF THE DIABETES SYMPTOM CHECKLIST- REVISED (DSC-R)- FACE, CONTENT AND CONSTRUCT VALIDITY

    Nov 1, 2007, 00:00

  • PND27 ESTIMATING MARGINAL COST-EFFECTIVENESS USING A PERSON-LEVEL NET BENEFITS APPROACH WITH AN APPLICATION TO DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS

    Nov 1, 2007, 00:00

  • PMH1 PRESCRIBING PATTERNS, PREDICTORS, AND COSTS ASSOCIATED WITH ANTIDEPRESSANT TREATMENTS FOR PERSONS WITH MAJOR DEPRSSIVE DISORDER (MDD) AND COMORBID PAIN

    Nov 1, 2007, 00:00

  • PEY12 METHODOLOGICAL ISSUES ARISING FROM THREE STUDIES WHICH INCLUDED CONJOINT ANALYSIS IN VISUALLY IMPAIRED PEOPLE

    Nov 1, 2007, 00:00

  • PMH39 ESTIMATION OF THE RESOURCE UTILIZATION AND METABOLIC CONTROL ASSOCIATED WITH DEPRESSIVE SYNDROME IN PATIENTS WITH STROKE

    Nov 1, 2007, 00:00

  • PDB42 COSTS ASSOCIATED WITH THE FIRST SIX MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY ANDTHE UNITED KINGDOM- DATA FROM THE INSTIGATE STUDY

    Nov 1, 2007, 00:00

  • PDB7 ADDITION OF INHALED HUMAN INSULIN AS AN OPTION FOR PATIENTS WITHTYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETICS SHOULD AVOID COMPLICATIONS PREDICTED BY EAGLE MODEL

    Nov 1, 2007, 00:00

  • Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis- The ESPRINT Questionnaire

    Nov 1, 2007, 00:00

  • PCN29 COST-EFFECTIVENESS OF MAINTENANCE RITUXIMAB TREATMENT AFTER SECOND LINE THERAPY IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPHOMA IN SWEDEN

    Nov 1, 2007, 00:00

  • PDB27 COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN CHINA

    Nov 1, 2007, 00:00

  • PAR29 AZATHIOPURINE, TPMT POLYMORPHISMS AND ADRS- THE COST OF NEUTROPENIA

    Nov 1, 2007, 00:00

  • CN4 COST-EFFECTIVENESS OF PEGYLATED LIPISOMAL DOXORUBICIN VS. CONVENTIONAL DOXORUBICIN IN AVOIDANCE OF CARDIOTOXICITY FOR METASTATIC BREAST CANCER IN THE FIRST TREATMENTYEAR

    Nov 1, 2007, 00:00

  • PCV66 COMPARING QUALITY OF CARE- IS IT MEANINGFUL?

    Nov 1, 2007, 00:00

  • PMH7 TREATMENT DURATION WITH ORAL AND LONG ACTING INJECTABLE FORMULATIONS OF TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA RESULTS ACROSS WORLD GEOGRAPHIES

    Nov 1, 2007, 00:00

  • PDB23 COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN A POLISH SETTING

    Nov 1, 2007, 00:00

  • PMC7 THE USE OF DISEASE TRANSMISSION MODELLING IN COST-EFFECTIVENESS ANALYSES- STRENGTHS AND WEAKNESSES

    Nov 1, 2007, 00:00

  • PCN12 COST-EFFECTIVENESS OFTARGETED ONCOLOGY THERAPIES-A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2007, 00:00

  • PCV8 EPROSARTAN VERSUS OTHERANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND IN PATIENTS WITH HYPERTENSION-INDIRECT ANALYSIS

    Nov 1, 2007, 00:00

  • The Mayo Clinic Manuscript Series Relative to the Discussion, Dissemination, and Operationalization of the Food and Drug Administration Guidance on Patient-Reported Outcomes

    Nov 1, 2007, 00:00

  • PHP3 BUDGET SILO MENTALITY BEHIND THE FORMER IRON CURTAIN-A CASE STUDY FROM HUNGARY

    Nov 1, 2007, 00:00

  • PIN11 COST-EFFECTIVENESS OF PEGINTERFERON-ALFA-2A (40 KD) ASSOCIATED WITH RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPES 2 AND 3 IN BRAZIL

    Nov 1, 2007, 00:00

  • PG15 EVALUATION OF THE COST-EFFECTIVENESS OF CONCOMITANT ORAL AND TOPICAL MESALAZINE TREATMENT VERSUS ORAL TREATMENT ALONE IN MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS- A DECISION-ANALYTIC MODEL

    Nov 1, 2007, 00:00

  • PIH19 TEMPORAL PATTERNS IN HEALTH RELATED QUALITY OF LIFE IN HOSPITALIZED PATIENTS IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PMC15 CONVERGENT, DISCRIMINANT, CONCURRENT VALIDITY AND RELIABILITY OF THE EQ-5D(CHILD)- RESULTS

    Nov 1, 2007, 00:00

  • CV2 COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN FROM A CANADIAN HEALTH CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • Quality of Life Related to Oral versus Subcutaneous Iron Chelation- A Time Trade-off Study

    Nov 1, 2007, 00:00

  • PR8 EVALUATION OF IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE USING ORAL MESALAZINE ALONE OR IN COMBINATION WITH A MESALAZINE ENEMA IN ACTIVE ULCERATIVE COLITIS- RESULTS FROM A RANDOMISED CONTROLLED TRIAL

    Nov 1, 2007, 00:00

  • PIH1 ASSOCIATION BETWEEN CENTRAL PRECOCIOUS PUBERTY AND COMORBID MEDICAL ILLNESS- LARGE-SCALE RETROSPECTIVE CLAIMS ANALYSIS OF FLORIDA MEDICAID-ENROLLED CHILDREN

    Nov 1, 2007, 00:00

  • PCN62 USE OF A 5-LEVEL EQ-5D IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

    Nov 1, 2007, 00:00

  • PCN68 SENSITIVITYTO CHANGE OF THE PERFORM QUESTIONNAIRE (PQ) IN CANCER PATIENTS REPORTING IMPROVEMENT OR DETERIORATION OF THEIR CANCER-RELATED FATIGUE

    Nov 1, 2007, 00:00

  • PIN46 A CROSS-SECTIONAL VALIDATION OF THE MINI-HIV QUESTIONNAIRE

    Nov 1, 2007, 00:00

  • PIH7 COST-EFFECTIVENESS OF MAGNETIC RESONANCE IMAGE-GUIDED FOCUSED ULTRASOUND (MRGFUS) FOR THE TREATMENT OF UTERINE FIBROIDS

    Nov 1, 2007, 00:00

  • PDB68 ISA MEASUREMENT-GUIDED INTERVENTION PROGRAM TO LENGTHEN PERSISTENCE WITH METFORMIN MONOTHERAPY COST EFFECTIVE IN TYPE 2 DIABETES?

    Nov 1, 2007, 00:00

  • PAA4 COST-EFFECTIVENESS ANALYSIS OF OMALIZUMABVS STANDARD THERAPY (ST), IN THE MANAGEMENT OF SEVERE ASHTMA

    Nov 1, 2007, 00:00

  • POS14 COMPARISON OF SF-6DAND EQ-5D UTILITIES IN OSTEOPOROTIC HIP FRACTURE PATIENTS

    Nov 1, 2007, 00:00

  • PRS1 ACUTE EFFECTS OF SILDENAFIL ON ECHOCARDIOGRAGHIC PARAMETERS IN PATIENTS WITH PRIMARY PULMONARY HYPERTENSION

    Nov 1, 2007, 00:00

  • PDB29 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS ANDTHE COMBINED EFFECT OF HBA1C AND HYPOGLYCAEMIA REDUCTION

    Nov 1, 2007, 00:00

  • PGI27 ESTIMATION OF WEIGHTS FOR THE SPANISH VERSION OF SF-6DTO DERIVE SOCIETAL HEALTH STATE VALUES USING THE SPANISH VERSION OF SF-36VI

    Nov 1, 2007, 00:00

  • PRS18 A PROCESS FOR DEVELOPING A PATIENT-CENTERED CONCEPTUAL FRAMEWORK FOR DYSPNEA AND RELATED FUNCTIONAL LIMITATIONS IN COPD

    Nov 1, 2007, 00:00

  • MC3 THE DEVELOPMENT OF AN INCREMENTAL WILLINGNESS TO PAY CURVE DERIVED FROM A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2007, 00:00

  • PDB41 INSULIN AND INSULIN ANCILLARY USAGE, THE ANNUAL COST OF TREATING TYPE 2 DIABETES WITH INSULIN IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • Patient-Reported Outcome Instrument Selection- Designing a Measurement Strategy

    Nov 1, 2007, 00:00

  • PCN7 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN SPAIN

    Nov 1, 2007, 00:00

  • PMH18 PRESCRIBING PATTERN OF CITALOPRAM AND ESCITALOPRAM IN THE CANTON OF GENEVA A POTENTIAL FOR MAJOR SAVINGS

    Nov 1, 2007, 00:00

  • PIH8 COST EFFECTIVENESS MODELLING OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS II, AN ULTRA-ORPHAN DISEASE

    Nov 1, 2007, 00:00

  • PSK13 PSYCHOMETRIC VALIDATION OF THE OILY SKIN SELF ASSESSMENT SCALE (OSSAS) AND THE OILY SKIN IMPACT SCALE (OSIS)

    Nov 1, 2007, 00:00

  • PCV62 PRIVATE PAYER EPISODE COSTS OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHYVS. MYOCARDIAL PERFUSION IMAGING FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE

    Nov 1, 2007, 00:00

  • POS3 THE ROLE OF SURGICAL DELAY ON EARLY MORTALITY IN PATIENTS WITH FEMORAL NECK FRACTURE

    Nov 1, 2007, 00:00

  • PDB36 INSULIN USE AND COSTS OF CARDIOVASCULAR DISEASE EVENTS (CVD) AMONG PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PST3 STROKE SURVIVORS' CHANGE IN HEALTH RELATED QUALITY OF LIFE OVERTIME AS MEASURED BYTHE STROKE IMPACT SCALE

    Nov 1, 2007, 00:00

  • PG111 IMPACT OF CONSTIPATION ON HEALTH CARE UTILIZATION AND COSTS IN PATIENTS ON OPIOID THERAPY

    Nov 1, 2007, 00:00

  • PCV90 INTEGRATION OF PATIENT-RATED OUTCOMES INTO CLINICAL ROUTINE IN INPATIENT AND OUTPATIENT CARDIAC REHABILITATION PROGRAMMES

    Nov 1, 2007, 00:00

  • PHP26 THE EFFECT OF INJURY SEVERITYANDTRAUMA CENTER DESIGNATION ON INPATIENT COSTS AND OUTCOMES IN HOSPITAL ADMISSIONS FORTRAUMATIC INJURY INTHE UNITED STATES

    Nov 1, 2007, 00:00

  • MC2 BAYESIAN MODELING OF RESOURCE USE ALONGSIDE MULTINATIONAL RANDOMISED CLINICAL TRIALS

    Nov 1, 2007, 00:00

  • PCV63 ESTIMATING A SOUTH AFRICAN PHARMACOECONOMIC THRESHOLD FOR PHARMACEUTICAL DECISION MAKING

    Nov 1, 2007, 00:00

  • PRS11 MARKOV MODEL FOR COPD- COMPARING TREEAGE AND ARENA SOFTWARE AND VALIDATING THE MODEL

    Nov 1, 2007, 00:00

  • PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)

    Nov 1, 2007, 00:00

  • PCN11 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA

    Nov 1, 2007, 00:00

  • PND19 ECONOMIC EVALUATION OF INTERFERON-Â-IB IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME (CIS)

    Nov 1, 2007, 00:00

  • PMC10 SPATIAL INTERPOLATION

    Nov 1, 2007, 00:00

  • PAR20 ASSOCIATION BETWEEN DOSE CHANGES AND HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTSWHO RECEIVED INFLIXIMAB THERAPY

    Nov 1, 2007, 00:00

  • PAR11 COST-EFFECTIVENESS OF ADDING LEFLUNOMIDE TO STANDARD DRUG SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN POLAND

    Nov 1, 2007, 00:00

  • PIH12 HORMONE REPLACEMENT THERAPY OF MENOPAUSAL WOMEN—ANALYSIS OF PRESCRIPTION PATTERN CHANGES BEFORE AND AFTER THE WHI STUDY USING CLAIMS DATA OF A GERMAN SICKNESS FUND

    Nov 1, 2007, 00:00

  • PAR17 A SYSTEMATIC REVIEW OFTHE GLOBAL COST-OF-ILLNESS OF RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PIN29 AZITHROMYCIN PLUS CEFTRIAXONE VERSUS LEVOFLOXACIN IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN SPAIN. A COST-MINIMIZATION ANALYSIS

    Nov 1, 2007, 00:00

  • PCN21 A HEALTH ECONOMIC EVALUATION OF HEXVIXAS ADJUNCT TO STANDARD WHITE LIGHT CYSTOSCOPY IN THE MANAGEMENT OF SUPERFICIAL BLADDER CANCER

    Nov 1, 2007, 00:00

  • PRS4 RELATIONSHIP BETWEEN TIME OF DURATION OF COPD AND FREQUENCY OF DISEASE EXACERBATIONS

    Nov 1, 2007, 00:00

  • Value in Health

    Nov 1, 2007, 00:00

  • PIN14 COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA SUSPECTED TO BE CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN SPAIN

    Nov 1, 2007, 00:00

  • PDB31 TOTAL COST REDUCTION IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS TREATED WITH PIOGLITAZONE (PIO) BASED THERAPIES VERSUS NON-THIAZOLIDINEDIONE (NON-TZD) BASED THERAPIES

    Nov 1, 2007, 00:00

  • PIN7 BURDEN OF PAEDIATRIC ROTAVIRUS GASTROENTERITIS AND POTENTIAL BENEFITS OF A UNIVERSAL VACCINATION PROGRAMME IN GERMANY

    Nov 1, 2007, 00:00

  • PRS7 ANALYSIS OF THE PREDICTIVE ABILITY OF DIAGNOSTIC COST GROUPS, RXGROUPS, AND PRIOR COST FORTEXAS MEDICAID COPD PATIENTS

    Nov 1, 2007, 00:00

  • PDB47 LONG-TERM ECONOMIC OUTCOMES ASSOCIATED WITH INSULIN ASPART VERSUS HUMAN BOLUS INSULIN IN TYPE 2 DIABETES PATIENTS IN THE SWEDISH SETTING

    Nov 1, 2007, 00:00

  • PHM23 PATIENTS', PHYSICIANS'AND PHARMACISTS' PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES TO TREAT PATIENTS WITH INHIBITORS- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2007, 00:00

  • PCV6 ESTIMATING THE INCREMENTAL BENEFIT ON FINAL OUTCOMES OF ROSUVASTATIN 40 MG OVER 20 MG IN THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLAEMIA BASED ON A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2007, 00:00

  • PDB4 A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ANDTHIAZOLIDINEDIONES (TZD) IN MONOTHERAPY

    Nov 1, 2007, 00:00

  • PMC27 VALIDATION OF THE CAT-HEALTH SYSTEM-THE FIRST COMPUTER-ADAPTIVE TESTING SYSTEM IN SPAIN FOR EVALUATING THE HEALTH RELATED QUALITY OF LIFE OF ILL OR HEALTHY GENERAL POPULATION SUBJECTS

    Nov 1, 2007, 00:00

  • RS3 IMPACT OF SOCIO-ECONOMIC FACTORS ON PATIENTS' KNOWLEDGE OFTHEIR CONDITION, INVOLVEMENT IN TREATMENT DECISIONS ANDTHE SUBSEQUENT COMPLIANCE WITHTHEIR TREATMENT REGIMEN

    Nov 1, 2007, 00:00

  • ES8 COST-EFFECTIVENESS OF DARUNAVIR/R IN HIGHLY TREATMENT-EXPERIENCED HIV/AIDS PATIENTS IN DIFFERENT EUROPEAN HEALTH CARE SETTINGS

    Nov 1, 2007, 00:00

  • PCV55 LIPID LOWERING AGENTS CONSUMPTION AND COSTS IN THE SLOVAK REPUBLIC

    Nov 1, 2007, 00:00

  • PAR19 COMPARISON OF ORAL LEFLUNOMIDE AND METOTREXATE SC FOR THE TREATMENT OF RHEUMATOID ARTHRITIS- AN APPROACH BASED ONTHE NUMBERTOTREAT

    Nov 1, 2007, 00:00

  • Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations

    Nov 1, 2007, 00:00

  • POS12 USE OF OSTEOPOROSIS MEDICATIONS FOLLOWING A FRACTURE

    Nov 1, 2007, 00:00

  • PHP31 EUROPEAN PRICING AND REIMBURSEMENT UPDATE- OPTIMAL MONETARY BENEFITS CAN DEPEND ON WHICH COUNTRYTHE PROCESS IS INITIATED

    Nov 1, 2007, 00:00

  • DB4 TREATMENT ADHERENCE AND BARRIERS TO ADHERENCE ARE ASSOCIATED WITH GLYCEMIC CONTROL AND EXPERIENCE OF HYPOGLYCEMIA AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE

    Nov 1, 2007, 00:00

  • POS6 COST-EFFECTIVENESS OF OSTEOPOROSIS SCREENING CAMPAIGN FOR BELGIAN WOMEN

    Nov 1, 2007, 00:00

  • PIN1 SYSTEMATIC REVIEW OF THE SAFETY OF ANTIRETROVIRAL THERAPIES FOR REDUCING THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION

    Nov 1, 2007, 00:00

  • PCN61 MULTI-STATE SURVIVAL ANALYSIS IN COST-EFFECTIVENESS STUDIES-THE CASE OF CAPECITABINE VERSUS DOCETAXEL IN METASTATIC BREAST CANCER (MBC) FORA PRIVATE PAYER IN BRAZIL

    Nov 1, 2007, 00:00

  • PPN5 LONGITUDINAL HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS)-A 12-WEEKS POST-HOC ANALYSIS OF THE PREGABALIN EFFECT UNDER ROUTINE MEDICAL PRACTICE

    Nov 1, 2007, 00:00

  • PUK3 REIMBURSEMENT INCENTIVE FOR PERITONEAL DIALYSIS MAY GENERATE BUDGET SAVINGS FOR ROMANIA

    Nov 1, 2007, 00:00

  • PHP9 INFLUENCE OF POLYPHARMACY BY APPLYING THE ADJUSTED CLINICAL GROUPS CLASSIFICATION IN A SPANISH POPULATION SETTING-A CROSS-SECTIONAL STUDY

    Nov 1, 2007, 00:00

  • ES3 COST-EFFECTIVENESS OF FIRST EYE CATARACT SURGERY IN ELDERLY WOMEN- A RANDOMISED CONTROLLED TRIAL

    Nov 1, 2007, 00:00

  • PAR31 MULTILEVEL ANALYSIS- A NOVEL APPROACH FOR STATISTICAL ANALYSIS OF LONGITUDINAL STUDIES IN ORTHOPAEDICS

    Nov 1, 2007, 00:00

  • PMH25 COST EFFETIVENESS OF AMISULPRID IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2007, 00:00

  • PMC9 PREVALENCE OF CONDITIONS IN THE US EMPLOYER INSURED POPULATIONS METHODOLOGY FOR PROJECTING FROM A CONVENIENCE SAMPLE

    Nov 1, 2007, 00:00

  • SU4 THE COST-EFFECTIVENESS OFTITANIUM CAGE VERSUS FEMORAL RING ALLOGRAFT IN CIRCUMFERENTIAL LUMBAR FUSION-A RANDOMISED CONTROLLED TRIAL

    Nov 1, 2007, 00:00

  • PMH31 A REVIEW OF PUBLISHED STUDIES ON THE BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED KINGDOM (UK)

    Nov 1, 2007, 00:00

  • International Price Comparisons for Novel and Follow-on Drugs

    Nov 1, 2007, 00:00

  • Interpreting and Reporting Results Based on Patient-Reported Outcomes

    Nov 1, 2007, 00:00

  • PCN77 PHARMACOECONOMIC ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NON-SMALL-CELL LUNG CANCER (NSCLC) IN TURKEY

    Nov 1, 2007, 00:00

  • PCV75 THE ANALYSIS OF HEALTH AND ECONOMIC BENEFITS AS THE CONSEQUENCE OF THE REALIZATION CARDIOVASCULAR SYSTEM DISEASES PREVENTION PROGRAMME AMONG THE CHILDREN AND YOUTH OF SCHOOL AGE IN POLAND

    Nov 1, 2007, 00:00

  • PMC30 ECONOMIC ADVANTAGES OF ONLINE DISCRETE EVENT SIMULATION TRAINING

    Nov 1, 2007, 00:00

  • PUK21 THE IMPACT OF ICODEXTRIN ON QUALITY OF LIFE IN DIABETIC PATIENTS ON PERITONEAL DIALYSIS OVERTIME- A REGRESSION ANALYSIS

    Nov 1, 2007, 00:00

  • PCN15 ESTIMATING THE COST EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCERVACCINATION IN IRELAND USING A MATHEMATICAL MODEL

    Nov 1, 2007, 00:00

  • PIN30 MULTI-CENTRE STUDY ON THE COSTS AND OUTCOMES OF ANTIBIOTIC TREATMENTS IN ITALY FOR COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI)

    Nov 1, 2007, 00:00

  • PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS

    Nov 1, 2007, 00:00

  • PMH52 USAGE AND PERSISTENCY OF ATYPICAL ANTI-PSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2007, 00:00

  • PND26 USE OF A COUNSELLING GUIDELINE FOR THE DETECTION OF DRUG RELATED PROBLEMS IN PARKINSON'S DISEASE

    Nov 1, 2007, 00:00

  • PST2 A CRITICAL REVIEW OF PUBLISHED ECONOMIC MODELLING STUDIES IN ISCHAEMIC STROKE

    Nov 1, 2007, 00:00

  • PHM15 POSITIVE INVESTMENT INTERVAL (PII)AND PAYBACK PERIOD (PP) OFFER DIFFERENT INTERPRETATIONS IN HEALTH TECHNOLOGY INVESTMENT DECISIONS- Pll ISA MATTER OF BEING AND PP IS A MATTER OF TURNING BENEFICIAL—A CASE OF HEMOPHILIA A

    Nov 1, 2007, 00:00

  • PCV16 HEALTH INSURANCE COSTS OF STROKE HOSPITAL TREATMENTS IN HUNGARY; 2003-2005

    Nov 1, 2007, 00:00

  • PPN8 CHRONIC PAIN TREATMENT WITH OPIOIDS- PRACTICE DOES NOT FOLLOW POLICY

    Nov 1, 2007, 00:00

  • PDB28 COST-EFFECTIVENESS ANALYSIS OF ACARBOSE IN THE PREVENTION OFTYPE 2 DIABETES IN SOUTH KOREA

    Nov 1, 2007, 00:00

  • PCV9 DIFFERENT REDUCTIONS OF HOSPITALISATIONS FOR CARDIOVASCULAR EVENTS AMONG 92035 USERS OF STATINS IN A REAL LIFE SETTING

    Nov 1, 2007, 00:00

  • PHM14 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) CHALLENGE TRANSFUSION RESOURCES NOW AND IN THE FUTURE

    Nov 1, 2007, 00:00

  • PMH23 COST-EFFECTIVENESS OF OLANZAPINE VERSUS GENERIC RISPERIDONE AND OTHER ANTIPSYCHOTICS IN STANDARD ORAL FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA IN THE US

    Nov 1, 2007, 00:00

  • PGI17 INCREASED INPATIENT UTILIZATION FOLLOWING COLECTOMY IN ULCERATIVE COLITIS IN THE MEDICARE POPULATION

    Nov 1, 2007, 00:00

  • PCN58 BREAST CANCER SCREENING PROGRAMS- EVALUATION ASIDE FROM CLINICAL AND ECONOMICAL ASPECTS

    Nov 1, 2007, 00:00

  • ND1 COST-EFFECTIVENESS OF INTRATHECAL BACLOFEN THERAPY VERSUS CURRENT THERAPIES IN DISABLED SPASTICITY

    Nov 1, 2007, 00:00

  • PCV10 MULTIPLE REGRESSION ANALYSIS MODEL PREDICTED DIASTOLIC BLOOD PRESSURE

    Nov 1, 2007, 00:00

  • PHP10 COMPLEMENT OR SUBSTITUTE? COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AND PRESCRIPTION DRUG USE AMONG AFRICAN AMERICANS

    Nov 1, 2007, 00:00

  • PIN26 THE COST-EFFECTIVENESS OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN HUNGARY

    Nov 1, 2007, 00:00

  • PMH51 ADHERENCE OF ALZHEIMER PATIENTS TO ANTIDEMENTIA DRUGS

    Nov 1, 2007, 00:00

  • PUK14 TIME SPENT ON ANAEMIA MANAGEMENT WITH ERYTHROPOIETIN STIMULATING AGENTS (ESA) IN HAEMODIALYSIS CENTRES- A CROSS-COUNTRIES PERSPECTIVE

    Nov 1, 2007, 00:00

  • PCN70 UTILITYVALUES FOR HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKAEMIA (CML)- ESTIMATES FROM LAYPERSONS IN AUSTRALIA, THE UNITED KINGDOM (UK) AND CANADA

    Nov 1, 2007, 00:00

  • PMS1 DIRECT HEALTH COSTS OF TREATING PATIENTS WITH FIBROMYALGIA IN PRIMARY CARE SETTINGS (PCS) UNDER ROUTINE MEDICAL PRACTICE-A COST OF ILLNESS STUDY USING A CLAIM DATABASE IN SPAIN

    Nov 1, 2007, 00:00

  • PCN25 PHARMACOECONOMIC EVALUATION OF CAPECITABINE (XELODA) FOR GASTRIC CANCER IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PDB51 DRUG USE FOR DIABETES MELLITUSTYPE 2 AND ITS COMPLICATIONS IN SLOVAKIA

    Nov 1, 2007, 00:00

  • PMH47 DEVELOPING COST-EFFECTIVE FORMULARIES- IMPLICATIONS FOR NEW ATYPICAL ANTIPSYCHOTICS

    Nov 1, 2007, 00:00

  • PG113 THE EPIDEMIOLOGY AND HEALTH CARE RESOURCE USE IN PATIENTS WITH CROHN'S DISEASE- A POPULATION BASED UK STUDY

    Nov 1, 2007, 00:00

  • PDB71 PILOT STUDY OF CLINICIAN ATTITUDES TO PUMP THERAPY- INTERNATIONAL DIFFERENCES AND THE NEED FORA GREATER UNDERSTANDING OF THE PATIENT PERSPECTIVE

    Nov 1, 2007, 00:00

  • PIH10 AN ECONOMIC ASSESSMENT OF THE CONTENT OF HOME PHARMACIES AND SELF MEDICATION PRACTICE AMONG FAMILIES IN SLOVAK REPUBLIC AND SERBIA CITIES

    Nov 1, 2007, 00:00

  • PCN19 A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W DA) COMPARED TO WEEKLY EPOETIN ALFA (QW EA) OR EPOETIN BETA (QW EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)-THE GERMAN CASE

    Nov 1, 2007, 00:00

  • PGI29 UPPER Gl SYMPTOMS IN GREEK PATIENTS RECEIVING ASPIRIN/NSAIDS

    Nov 1, 2007, 00:00

  • PMC23 VALIDITY OF THE SPANISH SF-6D TARIFFS AND EQ-5D COMPARING THE UTILITY VALUES OBTAINED IN FOUR DIFFERENT GROUPS OF PATIENTS

    Nov 1, 2007, 00:00

  • PCV58 COMPARISON OF REASONS BEHIND PHYSICIANS' ANTIHYPERTENSIVE THERAPY CHOICE IN THE UNITED STATES (US) AND EUROPE

    Nov 1, 2007, 00:00

  • PCV13 RISK OF MAJOR BLEEDING DURING CONCOMITANT USE OF ANTIBIOTIC DRUGS AND COUMARIN ANTICOAGULANTS

    Nov 1, 2007, 00:00

  • PSK7 EVALUATION OF THE ASSOCIATION BETWEEN PSORIASIS SEVERITY AND HOSPITAL RESOURCE USE IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PIN5 COST-EFFECTIVENESS OFTIGECYLINE IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN GERMANY

    Nov 1, 2007, 00:00

  • PCV68 CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS)

    Nov 1, 2007, 00:00

  • PCV88 QUALITY OF LIFE AS A PREDICTOR OF TREATMENT COMPLIANCE DURING ROUTINE HYPERTENSION MANAGEMENT- RESULTS OF PROSPECTIVE EVALUATION

    Nov 1, 2007, 00:00

  • Development, Validation, and Application of a Microsimulation Model to Predict Stroke and Mortality in Medically Managed Asymptomatic Patients with Significant Carotid Artery Stenosis

    Nov 1, 2007, 00:00

  • PHM18 BEST-WORST CASE SCALING IN DISCRETE CHOICE EXPERIMENTS- AN APPLICATION IN A RARE DISEASE POPULATION

    Nov 1, 2007, 00:00

  • PCV20 EVALUATING GENDER DIFFERENCES IN HEALTH CARE RESOURCE USE AND OUTCOMES AMONG ELDERLY PATIENTS WITH CONGESTIVE HEART FAILURE

    Nov 1, 2007, 00:00

  • MC1 ASSESSING THE GENERALISABILITY OF COST EVALUATION RESULTS USING THE EUCLIDEAN METRIC AND PRINCIPAL COMPONENTS ANALYSIS- LESSON FROM A HIGH-COST INNOVATION IN ONCOLOGY

    Nov 1, 2007, 00:00

  • PAR22 COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH ABATACEPT (ORENCIA) FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PDB25 COST-EFFECTIVENESS OF DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A BELGIUM SETTING, A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OFTHREE CLINICAL TRIALS

    Nov 1, 2007, 00:00

  • Performance Comparison of Likert and Binary Formats of SF-36 Version 1.6 Across ECRHS II Adults Populations

    Nov 1, 2007, 00:00

  • PHM4 CLINICO-ECONOMICAL ANALYSIS OF FERRUM LEKVS FENULS IN IRON-DEFICIENT ANEMIA IN ELDERLY PATIENTS

    Nov 1, 2007, 00:00

  • ES2/PMH44 COSTS AND OUTCOMES OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF ACUTE SCHIZOPHRENIA

    Nov 1, 2007, 00:00

  • PHP17 RECOMMENDATIONS FROM REIMBURSEMENT AGENCIES FORADDITIONAL POST-LAUNCH RESEARCH. THE NEXT HURDLE

    Nov 1, 2007, 00:00

  • PAR6 A COST EFFECTIVENESS PRELIMINARY STUDY ON A NEW TOTAL KNEE ARTHROPLASTY SYSTEM AND A PERIPHERAL NERVE BLOCKADETECHNIQUE

    Nov 1, 2007, 00:00

  • PND14 COST-EFFECTIVENESS OF PREGABALIN ADD-ON MEDICATION IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY IN FINLAND

    Nov 1, 2007, 00:00

  • PCN48 SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)—AN ECONOMIC EVALUATION USING BAYESIAN APPROACH

    Nov 1, 2007, 00:00

  • PCV34 COST-EFFECTIVENESS OF ATORVASTATIN PLUS AMLODIPINE VERSUS ATORVASTATIN PLUS ATENOLOL IN HYPERTENSIVE PATIENTS WITHOUT PREVIOUS CORONARY HEART DISEASE, NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS AND AT LEAST 3 CARDIOVASCULAR RISK FAC ...

    Nov 1, 2007, 00:00

  • PCV23 HOSPITAL COSTS FORTREATMENT OF ACUTE HEART FAILURE- ECONOMIC ANALYSIS OF THE REVIVE II STUDY

    Nov 1, 2007, 00:00

  • PHP28 DEVELOPMENT OF THE CAT-HEALTH SYSTEM-THE FIRST COMPUTER-ADAPTIVE TESTING SYSTEM IN SPAIN FOR EVALUATING THE HEALTH RELATED QUALITY OF LIFE OF ILL OR HEALTHY GENERAL POPULATION SUBJECTS

    Nov 1, 2007, 00:00

  • HP3 ASSESSING THE IMPACT OF A NATIONAL DRUG BENEFIT PROGRAM ONTHE USE OF GENERIC DRUGS AND DIFFERENT THERAPEUTIC CLASSES

    Nov 1, 2007, 00:00

  • PAA19 BI-MODALITY IN DISTRIBUTION OF MEDICATION POSSESSION RATIOS FOR ASTHMA CONTROLLER THERAPIES

    Nov 1, 2007, 00:00

  • PHP27 A NEW REGRESSION MODEL AND QUALITY PERFORMANCE ADJUSTMENT IN PHYSICIAN ECONOMIC PROFILING

    Nov 1, 2007, 00:00

  • PCV7 DIFFERENCES IN CHOLESTEROL LEVELS BETWEEN STATIN AND FIBRATE TREATED PATIENTS IN FRENCH, ITALIAN AND UNITED KINGDOM PRIMARY CARE

    Nov 1, 2007, 00:00

  • PCN27 COST-EFFECTIVENESS OF HUMAN INTERFERON-ALPHAAS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED CUTANEOUS MALIGNANT MELANOMA IN STAGE MB III

    Nov 1, 2007, 00:00

  • PUK5 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH CYCLOSPORINE A GENERICS FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION

    Nov 1, 2007, 00:00

  • PR6 PATIENT CHARACTERISTICS IMPACTING QUALITY OF LIFE (EQ-5D) OF FEMALES WITH STRESS URINARY INCONTINENCE SYMPTOMS

    Nov 1, 2007, 00:00

  • PCV86 THE IMPACT OF LOWERING SYSTOLIC BLOOD PRESSURE ON THE QUALITY OF LIFE OF HYPERTENSIVE PATIENTS IN GREECE-THE ECON-APROS STUDY

    Nov 1, 2007, 00:00

  • PMH33 AN EVALUATION OF HEALTH CARE COSTS WITH A DISEASE MANAGEMENT PROGRAM FOR ADULTS WITH SCHIZOPHRENIA IN A MEDICAID POPULATION USING PROPENSITY SCORE MATCHING

    Nov 1, 2007, 00:00

  • PPN1 INCIDENCE OF ACUTE PAIN IN TURKEY

    Nov 1, 2007, 00:00

  • PSU4 RETROSPECTIVE STUDY OF COMPLICATIONS AND RESOURCE USE IN ENDOVASCULAR MANAGEMENT OF AAA

    Nov 1, 2007, 00:00

  • PSK4 COST COMPARISON BETWEEN TWO ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPIES IN PATIENTS WITH PSORIASIS USING AVERAGE SALES PRICE

    Nov 1, 2007, 00:00

  • PAR14 COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2007, 00:00

  • PMC8 THE USE OF ADMNISTRATIVE DATABASE IN ITALY- INSIGHTS FROM THE FRIULIVENEZIA GIULIA CASE

    Nov 1, 2007, 00:00

  • PHP16 ASSESSMENT OF DECISION MAKER NEEDS RELATED TO HEALTH ECONOMIC MODELS AND DATA ANALYSIS TOOLS

    Nov 1, 2007, 00:00

  • PCV14 CHARACTERIZATION, RISK FACTORS, CLINICAL OUTCOMES, AND ECONOMIC CONSEQUENCES OF BLEEDING ASSOCIATED WITH CARDIAC SURGERY- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2007, 00:00

  • PHP2 A DETERMINATION OF TOPICS FOR HEALTH TECHNOLOGY ASSESSMENT IN THAILAND

    Nov 1, 2007, 00:00

  • PAR30 SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PEY1O- OXIDATIVE STRESS IN ADVANCED PRIMARY OPEN-ANGLE GLAUCOMA

    Nov 1, 2007, 00:00

  • Development and Validation of the Congestion Quantifier Seven-Item Test (CQ7)- A Screening Tool for Nasal Congestion

    Nov 1, 2007, 00:00

  • PCV5 EPROSARTAN VERSUS OTHERANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND (IRBESARTAN, LOSARTAN, TELMISARTAN AND VALSARTAN) IN PATIENTS WITH HYPERTENSION-DIRECT ANALYSIS

    Nov 1, 2007, 00:00

  • PND34 A QUALITATIVE STUDY OF THE INDIVIDUALISED IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE

    Nov 1, 2007, 00:00

  • PUK15 AN INTERNATIONAL ECONOMIC EVALUATION OF SEVELAMER HYDROCHLORIDE VERSUS CALCIUM-BASED PHOSPHATE BINDERS IN PATIENTS NEW TO DIALYSIS

    Nov 1, 2007, 00:00

  • PIN2 THE NATIONAL HEALTH FOUND BUDGET IMPACT ANALYSIS OF INFLUENZA VACCINATION REIMBURSEMENT IN CHILDREN WITH MALIGNANCIES IN POLAND

    Nov 1, 2007, 00:00

  • PMC2 A BAYESIAN ADAPTIVE DESIGN FOR EVALUATION OF THE GAP BETWEEN EFFICACY AND ERROR-ADJUSTED EFFECTIVENESS

    Nov 1, 2007, 00:00

  • PCV18 ECONOMIC BENEFIT OF IMPROVED PRESERVATION OF EXPLANTED ORGANS IN HEART TRANSPLANTATION

    Nov 1, 2007, 00:00

  • PCN51 COMPARING THE BURDEN OF CANCER AND OTHER DISEASES WITH THE ECONOMIC RESOURCES ALLOCATED TO THOSE DISEASES- A SOUTH AFRICAN PERSPECTIVE

    Nov 1, 2007, 00:00

  • PPN12 TURKISH MCGILL PAIN QUESTIONNAIRE- RELIABILITY AND VALIDATION

    Nov 1, 2007, 00:00

  • PDB56 FACTORS RELATED TO CSII USE AND REASONS FOR DISCONTINUATION

    Nov 1, 2007, 00:00

  • Analysis and Interpretation of Results Based on Patient-Reported Outcomes

    Nov 1, 2007, 00:00

  • PIN28 A COST MINIMIZATION ANALYSIS COMPARING DIFFERENT ANTIBIOTIC REGIMENS USED IN TREATING PNEUMONIA IN HONG KONG

    Nov 1, 2007, 00:00

  • PDB77 BARRIERS TO INSULIN THERAPY QUESTIONNAIRE- HOW TO USE THE “BIT” IN DAILY PRACTICE AND SCIENCE?

    Nov 1, 2007, 00:00

  • PCN4 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING HEXAMINOLEVULINATE (HEXVIX) CYSTOSCOPY COMPARED TOWHITE LIGHT CYSTOSCOPY IN BLADDER CANCER PATIENTS

    Nov 1, 2007, 00:00

  • PCN17 COST-EFFECTIVENESS ANALYSIS OFTRASTUZUMAB THERAPY IN PATIENTS WITH EARLY HER-2 POSITIVE BREAST CANCER IN BRAZIL

    Nov 1, 2007, 00:00

  • PCV73 ATOOL FOR MODELING MORTALITY DIFFERENCES IN PREDICTIVE SCREENING MODELS

    Nov 1, 2007, 00:00

  • PCN39 THE COST OF TREATING AND MANAGING ABNORMAL CERVICAL CONDITIONS IN IRELAND

    Nov 1, 2007, 00:00

  • PSK1 IMPACT OF SECONDARY PROPHYLACTIC USE OF TACROLIMUS 0.1% OINTMENT ON QUALITY-OF-LIFE, TREATMENT OUTCOMES AND COSTS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

    Nov 1, 2007, 00:00

  • PND8 COST-EFFECTIVENESS ANALYSIS OF AMBULATORY CARE STRATEGY FOR PATIENTS WITH TRANSIENT ISCHEMIC ACCIDENT (TIA) VERSUS THE STANDARD PROTOCOL BASED ON HOSPITALISATION

    Nov 1, 2007, 00:00

  • PSK6 IMPACT OF PSORIASIS DISEASE ON ANNUAL TOTAL HEALTH CARE COSTS AND RESOURCE UTILIZATION AMONG MEDICAID RECIPIENTS

    Nov 1, 2007, 00:00

  • PDB8 EVALUATION OF THE ASSOCIATION BETWEEN GLUCOSE VARIABILITY, AS MEASURED BY THE DIFFERENCE BETWEEN MAXIMUM AND MINIMUM, INTERMITTENT, RANDOM BLOOD GLUCOSE OBSERVATIONS, AND LONGTERM CLINICAL OUTCOME IN SUBJECTS WITHTYPE 2 DIABETES TREATE ...

    Nov 1, 2007, 00:00

  • PHM10 COST OF TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES (MDS) IN GERMANY

    Nov 1, 2007, 00:00

  • PIH5 COSTS AND OUTCOMES ASSOCIATED WITH USE OF RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH) DURING IN VITRO FERTILISATION (IVF) TREATMENT IN A UNITED KINGDOM CENTRE

    Nov 1, 2007, 00:00

  • ED2 LONG-TERM COST-UTILITY ANALYSIS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN INTYPE 2 DIABETES PATIENTS IN THE GERMAN SETTING

    Nov 1, 2007, 00:00

  • PRS6 ECONOMIC BURDEN OF DISEASE OF PULMONARY ARTERIAL HYPERTENSION IN GERMANY- AN INTERIM ANALYSIS OF RESOURCE UTILISATION

    Nov 1, 2007, 00:00

  • PAR9 A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES OF BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • DB3 CLINICAL AND PATIENT REPORTED OUTCOMES OVER THE FIRST 6 MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY ANDTHE UNITED KINGDOM- DATA FROMTHE INSTIGATE STUDY

    Nov 1, 2007, 00:00

  • PDB38 COST OF ILLNESS STUDY OFTYPE-2 DIABETES IN COLOMBIA

    Nov 1, 2007, 00:00

  • PMC20 UTILITYWEIGHTED COMPAREDTO UNWEIGHTED EQ-5D AND HUI3 SUMMARY SCORES- IMPLICATIONS FOR STATISTICAL INFERENCE

    Nov 1, 2007, 00:00

  • PDB24 A PHARMACOECONOMIC COMPARISON BETWEEN ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH DIABETIC NEPHROPATHY

    Nov 1, 2007, 00:00

  • PCV91 HEALTH OUTCOMES IN PATIENTS WITH HYPERTENSION- WHAT HAVE WE IMPROVED IN TEN YEARS?

    Nov 1, 2007, 00:00

  • PDB44 INPATIENT COSTS AND HEALTH OUTCOMES FOR PREGNANT WOMEN WITH TYPE I DIABETES

    Nov 1, 2007, 00:00

  • PHP5 DOES ENTRY OF GENERIC DRUGS ALWAYS RESULT IN COST-CONTAINMENT? THE HUNGARIAN EVIDENCE

    Nov 1, 2007, 00:00

  • PUK16 GLOBAL ECONOMIC EVALUATIONS OF DIALYSIS TREATMENT MODALITIES

    Nov 1, 2007, 00:00

  • PDB54 FACTORS ASSOCIATED WITH CONTINUED CLINICAL INERTIA AMONG PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • CASE2 ISSUES WHEN COMPARING COSTS AND EFFECTS OF INHALED ASTHMA AND COPD MEDICATIONS

    Nov 1, 2007, 00:00

  • PRS13 CEPOC STUDY- DIAGNOSTIC VALIDITY OF INDIRECT METHOS FOR COMPLIANCE ASSESSMENT IN COPD PATIENTS

    Nov 1, 2007, 00:00

  • PIN17 ESTIMATING THE LONG-TERM HEALTH AND ECONOMIC IMPACT OF A PROPHYLACTIC CERVICAL CANCERVACCINE ON THE BURDEN OF CERVICAL DISEASE IN ITALY

    Nov 1, 2007, 00:00

  • PR5 VALIDATION OF POMS QUESTIONNAIRE IN POSTMENOPAUSALWOMEN

    Nov 1, 2007, 00:00

  • PIN6 EPIDEMIOLOGIC AND ECONOMIC IMPACT OF ROUTINE VACCINATION OF INFANTS AGAINST ROTAVIRUS GASTROENTERITIS IN GERMANY- A PRELIMINARY ANALYSIS

    Nov 1, 2007, 00:00

  • PHP25 MEDICATION ADHERENCE IN POST-TRANSPLANT IMMUNOSUPPRESSION-THE ECONOMIC IMPACT OF DRUG-REGIMEN COMPLEXITY

    Nov 1, 2007, 00:00

  • PND38 LONGITUDINAL PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA- A POST-HOC ANALYSIS OF A 12-WEEK PROSPECTIVE STUDY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE

    Nov 1, 2007, 00:00

  • PUK12 THE ECONOMIC BURDEN OF HAEMODIALYSIS IN GREECE DURING 2006

    Nov 1, 2007, 00:00

  • PGI20 MAINTENANCE THERAPY WITH INFLIXIMAB REDUCES HOSPITALIZARON AND SURGERY IN CROHN'S DISEASE

    Nov 1, 2007, 00:00

  • PCV70 MULTINOMIAL PROPENSITY SCORE ESTIMATORS AND MULTIVARIATE EXPLANATORYTECHNIQUES IN A REAL-LIFE ACUTE CORONARY HEART DISEASE STUDY—THE QALYS AND COSTS OF MEDICATION, PTCAAND CABG TREATMENT MODALITY ARE HIGHLY DEPENDENT ON THE METHODS US ...

    Nov 1, 2007, 00:00

  • PCV45 COST-UTILITY ANALYSIS OF RIMONABANT IN THE MANAGEMENT OF OBESITY/OVERWEIGHT PATIENTS WITH CARDIOMETABOLIC RISK FACTORS IN HUNGARY

    Nov 1, 2007, 00:00

  • PIN4 COST-BENEFIT ANALYSIS OF OSELTAMIVIR VERSUS NO ANTIVIRAL TREATMENT FROM THE EMPLOYER PERSPECTIVE-THE ROCHE BRAZIL CASE

    Nov 1, 2007, 00:00

  • PDB53 AN EVALUATION OF TREATMENT DISCONTINUATION PATTERNS IN PEOPLE WITH TYPE I AND TYPE 2 DIABETES SWITCHED TO ALTERNATIVE SHORT ACTING INSULIN REGIMENS IN UK GENERAL PRACTICE

    Nov 1, 2007, 00:00

  • PGI16 AN EXPLORATORY ANALYSIS OF HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH PEDIATRIC CROHN'S DISEASE

    Nov 1, 2007, 00:00

  • PCV32 COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION, TYPE-2 DIABETES AND RENAL DAMAGE IN MEXICO

    Nov 1, 2007, 00:00

  • PAR5 ADALIMUMAB, ETANERCEPT OR INFLIXIMAB- WHAT IS THE MOST COST-EFFECTIVE ANTI-TNF-á THERAPY IN RA IN A REAL-WORLD SETTING?

    Nov 1, 2007, 00:00

  • PCV30 COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION—A EUROPEAN MODEL BASED ON THE CLARITY AND COMMITTRIALS- ADAPTATION TO HUNGARY

    Nov 1, 2007, 00:00

  • PCV12 USING ADMINISTRATIVE DATA FOR QUALITY INDICATORS OF AMI HOSPITAL CARE IN HUNGARY

    Nov 1, 2007, 00:00

  • PPN3 EXPECTED COST AND COST CONSIDERATIONS ASSOCIATED WITH OPIOID ROTATION FOR CHRONIC NON-CANCER PAIN- A SIMULATION MODEL

    Nov 1, 2007, 00:00

  • POS1 EFFICACY OF ZOLEDRONIC ACID RELATIVE TO OTHER TREATMENTS FOR VERTEBRAL FRACTURES IN OSTEOPOROSIS- RESULTS OF A BAYESIAN MIXED TREATMENT COMPARISON

    Nov 1, 2007, 00:00

  • PDB33 COST EFFECTIVENESS OF JANUVIA VERSUS AVANDIA AS SUPPLEMENTARY TREATMENT IN COMBINATION WITH METFORMIN FOR PATIENTS WITHTYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PHP15 PREFERENCES FOR DRUG REIMBURSEMENT CRITERIA IN SOUTH KOREA USING DISCRETE CHOICE EXPERIMENTS

    Nov 1, 2007, 00:00

  • PIN44 INCORPORATING PROBABILISTIC ATTRIBUTES IN A STATED-CHOICE RISK-BENEFIT SURVEY

    Nov 1, 2007, 00:00

  • PAA21 DEVELOPMENT OF A COST-UTILITY MODEL FOR COMPARING GINA STEP 3 ASTHMA MEDICATIONS BASED ON UTILITY AND SAFETY DATA DERIVED FROM A LARGE HEAD-TO-HEAD TRIAL OF MONTELUKAST AND SALMETEROL

    Nov 1, 2007, 00:00

  • PAR16 COST OF ANKYLOSING SPONDYLITIS IN CZECH REPUBLIC—DIRECT AND INDIRECT COSTS

    Nov 1, 2007, 00:00

  • PND17 TREATMENT COSTS ASSOCIATED WITH RESTLESS LEGS SYNDROME IN ITALY

    Nov 1, 2007, 00:00

  • PGI22 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND UTILITY SCORES FROM EQ-5D OR SF-6D IN CROHN'S DISEASE

    Nov 1, 2007, 00:00

  • PAR21 IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH CARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PCN53 EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN OVER 64 YEARS

    Nov 1, 2007, 00:00

  • SU2 MICRO-COSTING OF SURGICAL PROCEDURES RELATED TO INTRACEREBRAL HAEMORRHAGE IN A UK HEALTH CARE SETTING

    Nov 1, 2007, 00:00

  • PND25 TREATMENT PATTERNS AND PATIENT CHARACTERISTICS IN PARKINSON'S DISEASE (PD)- RESULTS FROM A LARGE MULTI-CENTER NEUROMONITOR INITIATIVE IN SPAIN

    Nov 1, 2007, 00:00

  • PCV2 EFFECTIVENESS OF MULTIPLE-MECHANISM ANTIHYPERTENSIVE MEDICATION- VALSARTAN-AMLODIPINE-HCTZ TRIPLE-THERAPY IN PRIMARY CARE

    Nov 1, 2007, 00:00

  • PHP38 PREVALENCE OF PALLIATIVE CARE NEEDS IN A COMMUNITY-BASED PUBLIC HOSPITAL

    Nov 1, 2007, 00:00

  • PCV40 STUDY OF THE COST OF OUTPATIENT HYPERTENSION THERAPY IN BULGARIA

    Nov 1, 2007, 00:00

  • PCN72 HEALTH-RELATED QUALITY OF LIFE (HRQOL)AND KIDNEY CANCER-RELATED SYMPTOMS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)TREATED WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA IN A RANDOMISED, MULTINATIONAL PHASE III TRIAL- RESULT ...

    Nov 1, 2007, 00:00

  • PIN31 TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH SKIN AND SOFT TISSUE INFECTIONS IN BELGIUM

    Nov 1, 2007, 00:00

  • PG12 PROTON PUMP INHIBITORS FOR THE INITIAL TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GORD) SYMPTOMS IN PATIENTS WITH REFLUX OESOPHAGITIS- A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2007, 00:00

  • PIN13 COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN IN NOSOCOMIAL PNEUMONIA DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE

    Nov 1, 2007, 00:00

  • PCN66 DEFINING HEALTH STATE UTILITIES FOR HAND-FOOT-SYNDROME

    Nov 1, 2007, 00:00

  • PIH4 DRUG COSTS AT THE END OF LIFE

    Nov 1, 2007, 00:00

  • PAA3 A BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING A NEW EXTRAFINE COMBINATION (BECLOMETHASONE/FORMOTEROL) FOR THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SPAIN

    Nov 1, 2007, 00:00

  • PMC32 U.S. PHYSICIANS- A METHOD TO REPORT QUALITY MEASURES FOR CMS PAY-FOR-PERFORMANCE BONUS COMPENSATION

    Nov 1, 2007, 00:00

  • PCN44 ADJUVANTTRASTUZUMAB TREATMENT IN EARLY STAGE BREAST CANCER- COST-EFFECTIVENESS IN THE BELGIAN HEALTH CARE SETTING

    Nov 1, 2007, 00:00

  • PSK8 ASSESSMENT OF INVOLVED BODY SURFACE AREA (BSA) IN PSORIASIS PATIENTS. VALIDATION OF SOFTWARE ASSISTED DIAGNOSIS BSA FOR THE MANAGEMENT OF PSORIASIS

    Nov 1, 2007, 00:00

  • PCV72 EMPIRICAL EVALUATION OF THE PREDICTIVE PERFORMANCE OF CLASSIFICATION TOOLS IN CORONARY HEART DISEASE—P-COURSE, A NAIVE BAYES TOOL, OUTPERFORMS NOVEL LOGISTIC REGRESSION APPROACHES

    Nov 1, 2007, 00:00

  • PAR2 DOES RACE INFLUENCE A PATIENT'S LIKELIHOOD OF BEING PRESCRIBED SELECTIVE CYCLOOXYGENASE-2 INHIBITORS (COX-2S) VERSUS OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS) IN MEDICAID MANAGED CARE PLANS (MCOS)?

    Nov 1, 2007, 00:00

  • PMH58 IMPROVED SLEEP IMPACT IN GENERALIZED ANXIETY DISORDER WITH ZOLPIDEM TARTRATE EXTENDED-RELEASE

    Nov 1, 2007, 00:00

  • PND33 THE RELATIONSHIP BETWEEN THE MEDICATION POSSESSION RATIO AND PATIENT OUTCOMES- EVIDENCE FROM THE USE OF GLATIRAMER ACETATE

    Nov 1, 2007, 00:00

  • HP2 ASSOCIATIONS BETWEEN NEGATIVE SYMPTOMS, SERVICE USE, AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2007, 00:00

  • PMH12 24-MONTH TREATMENT DISCONTINUATION RATES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION (RLAI) VERSUS ORAL ANTIPSYCHOTICS- RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) ...

    Nov 1, 2007, 00:00

  • PDB10 UNDERSTANDING INSULIN THERAPY INITIATION FROM A PRIMARY CARE PERSPECTIVE IN THE UNITED KINGDOM USING LOCAL DATA

    Nov 1, 2007, 00:00

  • CV1 POST-AMI DRUGTHERAPY PERSISTENCE AND RISK OF REINFARCTION IN A MEDICAID POPULATION

    Nov 1, 2007, 00:00
  • «
  • 151
  • 152
  • 153 (current)
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • »